ReviewFrontiers in pharmacology2022
Omalizumab and IgE in the Control of Severe Allergic Asthma.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Treatment of bronchial asthma - A simplified overview.Lung India : official organ of Indian Chest Society · 2026Article
- Prevalence and association of elevated total serum IgE levels with ICU admissions and poor asthma control: a retrospective study in a tertiary hospital in Saudi Arabia.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025Article
- Asthma Biologics Across the T2 Spectrum of Inflammation in Severe Asthma: Biomarkers and Mechanism of Action.Journal of asthma and allergy · 2025Review
- A support vector machine-based tool for rapid pediatric asthma exacerbation risk assessment: development and nursing application.Frontiers in pediatrics · 2025Article
- Application of Biologics in the Treatment of Asthma in the Past Two Decades: A Bibliometric Analysis and Beyond.Journal of asthma and allergy · 2025Review
- Exploring the therapeutic potential of monoclonal antibodies targeting TSLP and IgE in asthma management.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Meta-analysis of the adoption of omalizumab in the treatment of pediatric allergic diseases.Heliyon · 2024Article
- Engineering nanoparticle therapeutics for food allergy.The Journal of allergy and clinical immunology · 2024Review
- Efficacy of omalizumab in adult patients with allergic bronchopulmonary aspergillosis: a multicentre study in China.Clinical and experimental medicine · 2024Article
- Retrospective analysis of laboratory results in 18 cases of severe asthma treated with omalizumab.American journal of clinical and experimental immunology · 2024Article
- Ciliary Functional Analysis in Chronic Rhinosinusitis with Polyps after Multimodal Intervention: Oral Corticosteroid, Functional Endoscopic Sinus Surgery, and Omalizumab Injection.Case reports in otolaryngology · 2024Article
- Comparison of the therapeutic effects of medication therapy, specific immunotherapy and anti-IgE (Omalizumab) in patients with hay fever.Frontiers in immunology · 2024Article
- Review
- Eosinophilic Airway Diseases: From Pathophysiological Mechanisms to Clinical Practice.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab, a human immunoglobulin (Ig)G1 antibody against IgE, is a therapeutic agent for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of omalizumab should be considered as an option in step 5 of treatment for patients with the most severe type of bronchial asthma. In patients with atopic asthma who are at a high risk of exacerbation, and in whom symptoms are poorly controlled despite treatment with inhaled corticosteroids, omalizumab is one of the few drugs that improves symptoms, reduces the risk of exacerbation, and improves the quality of life while offering a high level of safety. On the other hand, the associated treatment costs are high, and there are no clear methods to identify responders. A recent study suggested that evaluating the therapeutic effects and monitoring the pharmacokinetics of omalizumab could improve the success of omalizumab therapy. This review outlines the relationship between IgE-targeted therapy and the serum level of IgE to enhance the current understanding of the mechanism of omalizumab therapy. It also describes the clinical significance of measuring serum free IgE levels and monitoring omalizumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.